tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schnitzler M | Diabetes mellitus after kidney transplantation in the United States. | 2003 | Am. J. Transplant. | pmid:14510709 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Wen X et al. | Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27137884 |
| English RF et al. | Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. | 2002 | Am. J. Transplant. | pmid:12243498 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Abdelmalek MF et al. | Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. | 2012 | Am. J. Transplant. | pmid:22233522 |
| Gupta G et al. | Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. | 2015 | Am. J. Transplant. | pmid:25988397 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Suszynski TM et al. | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. | 2013 | Am. J. Transplant. | pmid:23432755 |
| Damon C et al. | Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. | 2017 | Am. J. Transplant. | pmid:27597269 |
| Shuker N et al. | A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. | 2016 | Am. J. Transplant. | pmid:26714287 |
| Flechner SM et al. | Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. | 2010 | Am. J. Transplant. | pmid:20883540 |
| BenÃtez CE et al. | ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20883560 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Arnold R et al. | Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. | 2013 | Am. J. Transplant. | pmid:23841745 |
| Hirsch HH et al. | BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. | 2016 | Am. J. Transplant. | pmid:26639422 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Bohl DL et al. | Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. | 2005 | Am. J. Transplant. | pmid:16095500 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Tan HP et al. | Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. | 2009 | Am. J. Transplant. | pmid:19120078 |
| Ashman N et al. | Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. | 2009 | Am. J. Transplant. | pmid:19120084 |
| Vongwiwatana A et al. | Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. | 2004 | Am. J. Transplant. | pmid:14678043 |
| Bressollette-Bodin C et al. | A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. | 2005 | Am. J. Transplant. | pmid:15996241 |
| De Simone P et al. | Everolimus with reduced tacrolimus in liver transplantation. | 2013 | Am. J. Transplant. | pmid:23601137 |
| Awadalla Y et al. | HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. | 2004 | Am. J. Transplant. | pmid:15367226 |
| Luther P and Baldwin D | Pioglitazone in the management of diabetes mellitus after transplantation. | 2004 | Am. J. Transplant. | pmid:15575920 |
| Cherukuri A et al. | An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. | 2012 | Am. J. Transplant. | pmid:22390816 |
| Dahm F et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15575921 |
| Pascher A et al. | Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. | 2015 | Am. J. Transplant. | pmid:25677074 |
| Chen G et al. | A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. | 2006 | Am. J. Transplant. | pmid:16539628 |
| Okabayashi T et al. | Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. | 2011 | Am. J. Transplant. | pmid:21883903 |
| Zheng H et al. | Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. | 2003 | Am. J. Transplant. | pmid:12694072 |
| Montgomery SP et al. | Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. | 2002 | Am. J. Transplant. | pmid:12118862 |
| Ahsan N et al. | Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. | 2002 | Am. J. Transplant. | pmid:12118902 |
| van Hooff JP et al. | Glucose metabolic disorder after transplantation. | 2007 | Am. J. Transplant. | pmid:17511670 |
| Silva HT et al. | One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17217442 |
| Heffron TG et al. | Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. | 2007 | Am. J. Transplant. | pmid:17511684 |
| Moench C et al. | Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. | 2007 | Am. J. Transplant. | pmid:17511685 |
| Tedesco-Silva H et al. | Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. | 2015 | Am. J. Transplant. | pmid:25988935 |
| Pech T et al. | Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. | 2012 | Am. J. Transplant. | pmid:22974463 |
| Gallon L et al. | Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. | 2006 | Am. J. Transplant. | pmid:16827862 |
| Grenda R et al. | A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. | 2006 | Am. J. Transplant. | pmid:16827869 |
| Teuteberg JJ et al. | Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. | 2010 | Am. J. Transplant. | pmid:19889126 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Turgut F and Akcay A | Renal function estimation in cirrhosis. | 2009 | Am. J. Transplant. | pmid:19519814 |
| Irish WD et al. | Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. | 2011 | Am. J. Transplant. | pmid:21564522 |
| Friman S et al. | Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. | 2011 | Am. J. Transplant. | pmid:21564523 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |
| Rogers J et al. | Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. | 2003 | Am. J. Transplant. | pmid:14510702 |